Pompilio G, Morabito A, Cortinovis DL, Integlia D. Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations. Grhta [Internet]. 2022 Jan. 31 [cited 2024 Nov. 23];9(1):22-9. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2351